The Department of Health and Human Services today delayed until July 1, 2019 implementation of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. "With skyrocketing prescription drug price increases presenting hospitals, health systems and patients with remarkable challenges, the 340B program is as critical as ever in helping provide access to health care services for vulnerable patients and communities,” said AHA Executive Vice President Tom Nickels. “The 340B ceiling price and civil monetary penalties rule were intended to shine needed light on drug manufacturer price increases and hold drug manufacturers accountable for price overcharging. These reasons are why we continue to be disappointed in the delays – including five times since the beginning of last year alone – of the final rule and in the short shrift given to the review of the latest public comments. The irony is not lost on us that drug manufacturers continue to lobby for increased reporting for hospitals and others while refusing any transparency on their part."

Related News Articles

Headline
Thirteen states yesterday filed a lawsuit challenging a Department of Homeland Security final rule limiting the ability of legal immigrants to adjust or extend…
Headline
The U.S. Court of Appeals for the District of Columbia Circuit reversed the voiding of a rule that included Medicare and private insurance payments when…
Headline
The Centers for Disease Control and Prevention has released the first in a new series of free online training courses to help health care organizations prevent…
Headline
The AHA today urged the Department of Health and Human Services not to finalize certain proposed revisions to a 2016 final rule implementing the Affordable…
Headline
The AHA today proposed additional actions that the Centers for Medicare…
Chairperson's File
Often quietly and out of the public eye, the vital work of advancing health in America happens on many fronts.